NASDAQ:VTRS - Nasdaq - US92556V1061 - Common Stock - Currency: USD
Overall VTRS gets a fundamental rating of 5 out of 10. We evaluated VTRS against 197 industry peers in the Pharmaceuticals industry. VTRS has a medium profitability rating, but doesn't score so well on its financial health evaluation. VTRS has a bad growth rate and is valued cheaply.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -1.53% | ||
ROE | -3.4% | ||
ROIC | 3.92% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 12.04% | ||
PM (TTM) | N/A | ||
GM | 41.65% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.75 | ||
Debt/FCF | 7.18 | ||
Altman-Z | 0.96 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.65 | ||
Quick Ratio | 0.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 2.85 | ||
Fwd PE | 3.36 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 4.61 | ||
EV/EBITDA | 4.74 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 6.35% |
7.56
+0.17 (+2.3%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 6.35% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 2.85 | ||
Fwd PE | 3.36 | ||
P/S | 0.61 | ||
P/FCF | 4.61 | ||
P/OCF | 3.92 | ||
P/B | 0.48 | ||
P/tB | N/A | ||
EV/EBITDA | 4.74 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -1.53% | ||
ROE | -3.4% | ||
ROCE | 4.97% | ||
ROIC | 3.92% | ||
ROICexc | 4.02% | ||
ROICexgc | 16.14% | ||
OM | 12.04% | ||
PM (TTM) | N/A | ||
GM | 41.65% | ||
FCFM | 13.27% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.75 | ||
Debt/FCF | 7.18 | ||
Debt/EBITDA | 3.01 | ||
Cap/Depr | 11.99% | ||
Cap/Sales | 2.35% | ||
Interest Coverage | 3.16 | ||
Cash Conversion | 49.33% | ||
Profit Quality | N/A | ||
Current Ratio | 1.65 | ||
Quick Ratio | 0.98 | ||
Altman-Z | 0.96 |